Zafgen (NASDAQ: ZFGN) issued the following statement:"Zafgen recently learned of a patient death which occurred in the Company’s ongoing double-blind ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments Trader Talk Trading Halts

Cowen Cuts Price Target on Zafgen (ZFGN) as Beloranib is Placed on Hold Following Patient Death October 16, 2015 1:28 PM Zafgen (ZFGN) PT Lowered to $46 at RBC Capital; Discusses Road Ahead for BeloranibOctober 15, 2015 7:17 AM Leerink Partners Comments on Zafgen (ZFGN) Following Patient DeathOctober 14, 2015 2:26 PM Zafgen (ZFGN) Worst Case Scenario Avoided, RBC Capital - BloombergOctober 14, 2015 1:18 PM Who Traded Zafgen (ZFGN) on Illegal Insider Information?October 14, 2015 12:54 PM Zafgen (ZFGN) Learns of Death in Beloranib Phase 3October 14, 2015 12:27 PM Zafgen (ZFGN) will resume trading at 12:30pm ETOctober 14, 2015 12:21 PM Zafgen Issues StatementOctober 14, 2015 11:59 AM Zafgen (ZFGN) Halted, News PendingOctober 14, 2015 11:48 AM Zafgen (ZFGN) Reportedly Defended at SuntrustOctober 14, 2015 11:00 AM